Vax4eU · Vaccinologists for Europe: Training network for developing next generation vaccines against mucosal pathogens

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

AntimicrobiaAntimicrobial resistance (AMR) and emerging viral pathogens pose significant global health threats, with mucosal infections contributing to severe morbidity and mortality. Current systemic immunization strategies fail to induce effective mucosal immunity, including tissue-resident memory cells (TRMs) and secretory IgA (sIgA). Addressing this gap requires targeted research and training in mucosal vaccinology. The Vax4eU network aims to advance next-generation mucosal vaccines through a multidisciplinary program for 16 Doctoral Candidates (DCs), focusing on vaccine candidates and technologies that induce robust mucosal immunity, prevent infection, and combat AMR.Vax4eU integrates cutting-edge approaches, including AI-assisted antigen design, novel adjuvants, and tailored nanoparticle delivery systems. Research spans the vaccine pipeline, from drug substance design to preclinical evaluation. Work Package (WP) 1 focuses on antigens and adjuvants, using platforms like mRNA and fusion proteins, along with mucosal-targeting strategies such as ""Blood2Gut"" adjuvants. WP 2 develops advanced delivery systems, including polysaccharide, protein, and lipid nanoparticles and innovative mucosal adjuvants like cyclic dimeric AMP. WP 3 identifies CoIs and CoPs using high-dimensional tools and preclinical models, including pigs, which closely mimic human mucosal immunity.The program combines research with robust training, offering DCs individualized projects, network-wide training in AI tools, regulatory processes, drug delivery, and preclinical studies. Collaboration with academic and non-academic partners ensures DCs gain insights into scientific and translational aspects of vaccinology, supported by secondments, expert mentoring, and interinstitutional collaboration.By advancing mucosal vaccine technology and addressing AMR, Vax4eU aligns with European public health priorities, fostering a new generation of skilled vaccinologists to tackle global infectious diseases.""

Original text from CORDIS.

Participants

• TECHNISCHE UNIVERSITAET MUENCHEN · MuenchenCoordinatorGermany
• Croda Denmark A/S · FrederikssundDenmark
• Evaxion · HørsholmCity levelDenmark
• Faculdade de Farmácia da Universidade de Lisboa · LisboaPortugal
• HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH · BraunschweigGermany
• INMUNOTEK SL · ALCALA DE HENARESCity levelSpain
• INSTITUT CURIE · ParisFrance
• KOBENHAVNS UNIVERSITET · KOBENHAVNDenmark
• LINQ MANAGEMENT GMBH · BERLINGermany
• STATENS SERUM INSTITUT · Kobenhavn SDenmark
• TECHNISCHE UNIVERSITAET BRAUNSCHWEIG · BraunschweigGermany
• THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinIreland
• UNIVERSIDAD COMPLUTENSE DE MADRID · MadridSpain
• UNIVERSIDAD DE NAVARRA · PamplonaSpain
• UNIVERSITAT ZURICH · ZurichSwitzerland
• UNIVERSITE PARIS SCIENCES ET LETTRES · ParisFrance
• UNIVERSITEIT ANTWERPEN · AntwerpenBelgium
• UNIVERSITY OF STRATHCLYDE · GlasgowUnited Kingdom
• VIB VZW · ZWIJNAARDE - GENTBelgium

Links

• View on CORDIS
• DOI: 10.3030/101311814